Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1504776

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Temporary Employment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the total cost to NHS hospitals was of using (a) agency and (b) bank staff in each region in England in the 2021-22 financial year.
tabling member constituency	Enfield North
tabling member printed	Feryal Clark
uin	47698
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>The information requested is not yet held in the format requested as the accounts for 2021/22 are currently being audited.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 20/09/2022 14:35:04 answering member 4320 label Biography information for Robert Jenrick previous answer version 17726 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4822 label Biography information for Feryal Clark

1504790

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the level of access to antiviral treatments for people who are acutely vulnerable to covid-19.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	47395
answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>For patients whose immune system means they are at the highest risk from COVID-19 and who test positive for the virus, treatments can be accessed directly through COVID Medicine Delivery Units (CMDUs). Those patients at high risk of COVID-19 who are ineligible to access treatments via CMDUs can access antivirals via the PANORAMIC national study.</p><p>The Department and NHS England are monitoring the uptake of antiviral treatment against those digitally identified as eligible. In England, 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the date of symptom onset.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:24:35 answering member 4320 label Biography information for Robert Jenrick previous answer version 17717 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	1506 label Biography information for Andrew Gwynne

1504791

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Monkeypox: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to accelerate resumption of the Monkeypox vaccination rollout.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	47396
answer	answer is ministerial correction date of answer 31/10/2022 answer text <p>The UK Health Security Agency (UKHSA) procured over 150,000 doses of Monkeypox vaccines, with 70,000 vials arriving in the United Kingdom by September and a further 80,000 vials in October.</p><p> </p><p>The UKHSA has endorsed the use of ‘fractional dosing’, in which people aged 18 years old and over can be offered a 0.1 millilitre dose of the Jynneos smallpox vaccine, replacing the 0.5 millilitre dose typically administered. This will enable up to a five-fold increase in the number of people offered vaccination with the same level of effectiveness.  There has been no pause in the programme since it began.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 31/10/2022 17:40:50 answering member 4679 label Biography information for Neil O'Brien previous answer version 17718 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	1506 label Biography information for Andrew Gwynne

1504818

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	47397
answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.</p><p>We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:27:13 answering member 4320 label Biography information for Robert Jenrick previous answer version 17719 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	1506 label Biography information for Andrew Gwynne

1504891

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Respiratory Syncytial Virus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, on what date he expects NHS England’s Palivizumab Expert Group to respond to the request from the JCVI to consider the eligibility of children with spinal muscular atrophy to receive the Palivizumab vaccination against respiratory syncytial virus.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47662
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47663 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17723 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4769 label Biography information for Daisy Cooper

1504892

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Respiratory Syncytial Virus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to recommendations in the consensus statement of the 2017 International Conference on the Standards of Care on the use of Palivizumab for some categories of children with spinal muscular atrophy to protect from respiratory syncytial virus, if he will take steps to urgently review the eligibility criteria for the Palivizumab vaccine.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	47663
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47662 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17724 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4769 label Biography information for Daisy Cooper

1504900

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Workers: Allowances
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will offer support to local authorities to help social care providers to increase the mileage allowance paid to care workers.
tabling member constituency	Stockport
tabling member printed	Navendu Mishra
uin	47691
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Under the Care Act 2014, local authorities have a duty to manage local care markets. The vast majority of care workers are employed by private sector providers which set their terms and conditions, including renumeration for travel costs, independently of Government. Local authorities work with care providers to determine fee rates, which should take account of employment costs, based on local market conditions.</p><p>We are committing £1.36 billion to the Market Sustainability and Fair Cost of Care Fund. The Fund will support local authorities to prepare markets for reform and move towards paying providers a fair cost of care. The Government continues to work with local government and care providers to understand the impact from challenges such as energy price rises and inflationary pressures.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 20/09/2022 14:35:49 answering member 4679 label Biography information for Neil O'Brien previous answer version 17725 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	4811 label Biography information for Navendu Mishra

1504906

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to (a) increase awareness of Sickle Cell disease and (b) improve the training for dealing with that disease among (i) nurses and doctors in training and (ii) practising NHS nurses and doctors.
tabling member constituency	East Ham
tabling member printed	Sir Stephen Timms
uin	47331
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>As part of this years’ World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.</p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council’s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.</p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report ‘No One’s Listening’ highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report’s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.</p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence’s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE’s guidelines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 47332 47333 question first answered 20/09/2022 14:27:53 answering member 4423 label Biography information for Will Quince previous answer version 17713 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	163 label Biography information for Sir Stephen Timms

1504908

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the level of awareness among NHS ambulance and A and E staff of the need for urgency in dealing with a Sickle Cell crisis.
tabling member constituency	East Ham
tabling member printed	Sir Stephen Timms
uin	47332
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>As part of this years’ World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.</p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council’s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.</p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report ‘No One’s Listening’ highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report’s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.</p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence’s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE’s guidelines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 47331 47333 question first answered 20/09/2022 14:27:53 answering member 4423 label Biography information for Will Quince previous answer version 17714 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	163 label Biography information for Sir Stephen Timms

1504909

registered interest
date	05/09/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Analgesics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of compliance in the NHS with NICE guidance that Sickle Cell patients should receive pain relief within 30 minutes of admittance to Accident and Emergency care; and if he will make a statement.
tabling member constituency	East Ham
tabling member printed	Sir Stephen Timms
uin	47333
answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>As part of this years’ World Sickle Cell Day, NHS England launched a new sickle cell disease awareness campaign on the signs and symptoms of sickle cell disease, aimed at urgent and emergency care staff and those living with the condition and their carers.</p><p>There have been recent improvements to the haematology medical curriculum, with understanding sickle cell disease and thalassemia now described in the curriculum as core competencies. Health Education England (HEE) provides e-learning which includes content on sickle cell disease. HEE has held discussions with the Royal Colleges of Pathology and Physicians to ensure this curriculum is deliverable to all four nations, in line with General Medical Council’s (GMC) standards. The Haemoglobinopathy Coordinating Centres also provide network development, leadership, learning and education.</p><p>The Sickle Cell Society and the All-Party Parliamentary Group on Sickle Cell and Thalassaemia report ‘No One’s Listening’ highlighted the lack of awareness of sickle cell disease among healthcare professionals. Officials are considering the report’s recommendations. NHS England estimates that awareness amongst accident and emergency medical and nursing staff, specifically of conditions such as sickle cell disease, is high across England and in areas where there is a higher prevalence of the condition. However, NHS England and other bodies continue with further awareness raising.</p><p>No specific assessment has been made regarding the extent of compliance to the National Institute for Health and Care Excellence’s (NICE) guidance on pain relief for sickle cell patients. The Care Quality Commission (CQC) considers evidence of how registered persons have met fundamental standards through its regulatory approach. The CQC will consider the processes providers have to ensure that best practice is implemented for quality standards, including NICE’s guidelines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 47331 47332 question first answered 20/09/2022 14:27:53 answering member 4423 label Biography information for Will Quince previous answer version 17715 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
tabling member	163 label Biography information for Sir Stephen Timms